SEATTLE, Washington and CAMBRIDGE, Massachusetts — September 8, 2026
BrainChild Bio, Inc. announced the initiation of the pivotal Phase 2 ILLUMINATE clinical trial evaluating BCB-276, an investigational B7-H3-targeted autologous CAR T cell therapy, in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The open-label, single-arm study is being conducted following initial standard-of-care focal radiation therapy and is designed as a pivotal registrational trial intended to support a potential Biologics License Application (BLA). BrainChild Bio said the trial design follows alignment with the U.S. Food and Drug Administration (FDA), while BCB-276 has also received Fast Track designation to support an expedited development and regulatory pathway. The multi-center ILLUMINATE study is being launched across six leading pediatric oncology centers in the United States, with site activation complete or underway at all selected locations.
ILLUMINATE Trial Targets a Major Unmet Need in Pediatric Oncology
The ILLUMINATE Phase 2 study is designed to evaluate the efficacy and confirm the safety of BCB-276 in patients with newly diagnosed DIPG, a highly aggressive pediatric brainstem tumor for which treatment options remain extremely limited. The primary endpoint is overall survival, while secondary endpoints include safety and tolerability, progression-free survival and radiographic response. Participants will receive BCB-276 approximately every two weeks, with a planned treatment course of up to 15 doses over approximately seven to eight months. BrainChild Bio is working with leading pediatric neuro-oncology investigators to execute the pivotal study across specialized centers, reflecting the complexity of clinical development in this rare disease. With the trial structured as a registrational Phase 2 program, the company is seeking to generate the clinical evidence needed for a potential regulatory submission while maintaining an accelerated development strategy for children facing a disease with a median overall survival of approximately 11 months under current standard treatment.
BCB-276 Uses Locoregional CAR T Cell Delivery
BCB-276 is manufactured from each participant’s own immune cells and delivered directly into the cerebrospinal fluid through an indwelling reservoir-catheter system. The locoregional approach is intended to address several challenges associated with treating tumors located within the brainstem, including the infiltrative nature of DIPG and limitations imposed by the blood-brain barrier. Direct administration into cerebrospinal fluid allows CAR T cells to access the tumor region and supports repeated dosing designed to provide sustained exposure. BrainChild Bio is also developing its broader CNS CAR T platform around technologies intended to improve delivery, persistence and therapeutic functionality while potentially limiting on-target, off-tumor toxicity. The company’s approach builds on work conducted by founder and Chief Scientific Officer Michael Jensen, M.D., and his team at Seattle Children’s, with the underlying CAR T technology exclusively licensed to BrainChild Bio for further development..
Advertisement
BrainChild Bio Builds on Phase 1 Clinical Foundation
The pivotal Phase 2 program follows clinical experience from the BrainChild-03 Phase 1 study, an FDA-authorized trial identified as NCT04185038. According to BrainChild Bio, the earlier study demonstrated a manageable safety profile in the context of outpatient administration and generated preliminary evidence of encouraging overall survival outcomes. Results from the Phase 1 trial were published in Nature Medicine, providing a clinical foundation for advancing the therapy into the pivotal ILLUMINATE program. BrainChild Bio is now expanding development of BCB-276 while building a broader next-generation CAR T cell platform for central nervous system tumors. The company’s platform incorporates synthetic biology approaches, including multiplex tumor targeting, strategies intended to enhance CAR T functionality, specialized delivery technologies and streamlined cell therapy design and manufacturing. With the ILLUMINATE study now underway, BrainChild Bio is positioning BCB-276 as its lead clinical program and establishing a potential regulatory pathway for a new treatment approach in pediatric DIPG.
Source: Sernova press release
